Therapeutic use of anti-TNF-α agents in spondyloarthropathies;Utilisation thérapeutique des agents anti-TNF-α au cours des spondylarthropathies

Presse Medicale

Volumn 32, Issue 32, 2003, Pages 1517-1524

  Wendling, Daniel ^a   Claudepierre, Pascal ^b   Lobse, Anne ^a   Toussirot, Eric ^a   Breban, Maxime ^c  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD20 ANTIGEN; CD4 ANTIGEN; CHIMERIC ANTIBODY; DECAY ACCELERATING FACTOR; DNA ANTIBODY; ETANERCEPT; GADOLINIUM; HLA B27 ANTIGEN; IMMUNOMODULATING AGENT; INFLIXIMAB; MESSENGER RNA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTEIN P75; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ANKYLOSING SPONDYLITIS; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CROHN DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; HUMAN; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PROGNOSIS; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REACTIVE ARTHRITIS; REMISSION; REVIEW; SCORING SYSTEM; SPONDYLOARTHROPATHY; TREATMENT INDICATION; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141998781     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Wendling D. Les spondylarthropathies: un concept utile au clinicien. La Lettre du Rhumatologue 2000; 261: 4-5.
2. Toussirot E, Wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 1998; 56: 225.40.
3. Wendling D. Spondylarthrite ankylosante. Encycl Med Chir, Apparell Locomoteur, 14-230-A-10, 1998.
4. Gratacos J, Collado A, Filella X et al. Serum cytokines (IL-6, TNF-α, IL-1α, IFNα) in ankylosing spondylitis: a close correlation between serum IL.6 and disease activity and severity. Br J Rheumatol 1994; 33: 927-31.
5. Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridisation techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
6. Wendling D. Rôle de l'intestin dans la physiopathologie des rhumatismes inflammatoires. Rev Rhum 1992; 59: 389-92.
7. May E, Marker-Hermann E, Wittig BM et al. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 2000; 119: 1745-55
8. Hanauer SB, Feagan BG, Lichtenstain GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541.9.
9. Breban M, Gombert B, Amor B, Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 1999; 42: 580-1.
10. Huang F, Gu J, Zhao W et al. One year open - label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum (Arthritis Care and Research) 2002; 47: 249-54.
11. Wendling D, Toussirot E, Michel F. Thalidomide: a comeback? Joint Bone Spine 2002: 67: 259-61
12. Meyer O. Place des thérapeutiques anti-TNF dans la polyarthrite rhumatoide. Presse Med 2000; 29: 463-8.
13. Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody Infliximab. Arthritis Rheum 2000; 43: 1346-52.
14. Wendling D, Toussirot E. Spondylarthropathies: critères et indices. Rhumatologie 1997; 49: 299-306.
15. Brandt J, Haibel H, Sieper J et al. Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum 2001; 44: 2936-7.
16. Stone I, Salonen D, Lax M et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001; 28: 1605-14.
17. Maksymowych WP, Jhangris GS, Lambert RG et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29: 959-65.
18. Breban M, Vignon E, Claudepierre P et al. Efficacy of Infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 2002; 41: 1280-5.
19. Anderson JJ, Baron G, Van Der Heude D et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-86.
20. Boeger CA, Wittner H, Schattenkirchner M, Kellner. Treatment of ankylosing spondylitis with Infliximab. Ann Rheum Dis 2001; 60: 1159-60.
21. Hadi A, Hickling P, Brown M, Al-Nahhas A. Scintigraphic evidence of effect of Infliximab on disease activity inankylosing spondylitis. Rheumatology 2002; 41: 114-16.
22. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with Infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
23. Van Den Bosch F, Kruithof E, Baeten D et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondylarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428-33.
24. Baeten D, Van Damme N, Van Den Bosch F et al. Impaired Th1 cytokine production in spondylarthropathy is restored by anti-TNFα. Ann Rheum Dis 2001; 60: 750-5.
25. Baeten D, Kruithof E, Van Den Bosch F et al. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondylarthropathy. Arthritis Rheum 2001; 44: 186-95.
26. Kruithof E, Van Den Bosch F, Baeten D et al. Repeated infusions of Infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002; 61: 207-12.
27. Brandt J, Haibel H, Reddig J et al. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-α monoclonal antibody Infliximab. J Rheumatol 2002; 29: 118-22.
28. D'Agostino MA, Breban M, Said-Nahal R, Dougados M. Refractory inflammatory heel pain in spondylarthropathy: a significant response to Infliximab documented by ultrasound Arthritis Rheum 2002; 46: 840-2.
29. Van Den Bosch F, Kruithof E, Baeten et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (Infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755-65.
30. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of Etanercept in the treatment of the enthesal pathology in resistant spondylarthropathy. Arthritis Rheum 2001; 44: 2112-17.
31. Gorman J, Sack K, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor (alpha). N Engl J Med 2002; 346: 1349-56.
32. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
33. Furst D, Keystone EC, Breedveld FC et al. Updated consensus statement on tumor necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (april 2001). Ann Rheum Dis 2001; 60: iii2-5.
34. Keane J, Gershon S, Wise R et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha - neutralizing agent. N Engl J Med 2001; 345: 1098-104.
35. GTI (Groupe Tuberculose et Infliximab), Afssaps. Recommandations concernant la prévention et la prise en charge des tuberculoses survenant sous Infliximab. Rev Rhum 2002; 69: 256-9.
36. Braun J, Sieper J. Anti-TNFα: a new dimension in the pharmacotherapy of the spondyloarthropathies. Ann Rheum Dis 2000; 59: 404-6.